[HTML][HTML] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …
developed as therapeutics and are a major contributor to neutralizing antibody responses …
[PDF][PDF] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - researchgate.net
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and make a major contribution to the neutralizing antibody …
developed as therapeutics and make a major contribution to the neutralizing antibody …
[HTML][HTML] Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - Cell Host & Microbe, 2021 - cell.com
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …
developed as therapeutics and are a major contributor to neutralizing antibody responses …
[引用][C] Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost… - Cell Host & …, 2021 - cir.nii.ac.jp
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that
Escape Antibody Recognition | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Escape Antibody Recognition | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - 2021 - cabidigitallibrary.org
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …
developed as therapeutics and are a major contributor to neutralizing antibody responses …
[PDF][PDF] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - academia.edu
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and make a major contribution to the neutralizing antibody …
developed as therapeutics and make a major contribution to the neutralizing antibody …
[PDF][PDF] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - research.fhcrc.org
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and make a major contribution to the neutralizing antibody …
developed as therapeutics and make a major contribution to the neutralizing antibody …
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost… - Cell Host and …, 2021 - profiles.wustl.edu
Greaney et al. develop a method to map all mutations to the SARS-CoV-2 RBD that escape
antibody binding and apply this method to 10 antibodies. The resulting escape maps predict …
antibody binding and apply this method to 10 antibodies. The resulting escape maps predict …
[PDF][PDF] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - scienceopen.com
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and make a major contribution to the neutralizing antibody …
developed as therapeutics and make a major contribution to the neutralizing antibody …
Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein… - 2020 - pesquisa.bvsalud.org
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and make a major contribution to the neutralizing antibody …
developed as therapeutics and make a major contribution to the neutralizing antibody …